My apols start again:
I would think that thecompany has to do a CR before the commencement (or in the early stages) of thePhase 2 trials.
Would it be preferable for the company to seek a NASDAQ listing and raise thecash via the IPO?Alternatively, a buyin by a downstream user?But it doesn’t appearthat the CR will occur in Australia.
Any views on this?
As a matter ofinterest, you may recall that ResMed started out as an Australian company witha CPAP invention. It now has some 8,000 employees and operatesin approx. 140 countries. It has manufacturing facilities in Australia,Singapore, France, and the US. ResMed is listed on both the ASX and the NYSE.There’s no reason why IBX can’t achieve a similar global outcome.
DISCLAIMER: I am notqualified in any of this and the above is my idle speculation only and notfinancial advice of any kind. So please do your own research.
Regards, Stretguy
